WuXi Biologics (Cayman) (MEX:2269N) Inventories, Finished Goods: MXN38 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:2269N WuXi Biologics (Cayman) Inc MEX:2269N
97 GF Score
Price MXN62.53
GF Value MXN54.50
! 5 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Inventories, Finished Goods?

WuXi Biologics (Cayman) MEX:2269N 97 Inventories, Finished Goods is MXN38 Mil as of Dec. 2025. GuruFocus rates MEX:2269N with a GF Score™ of 97/100 and a GF Value™ of MXN54.50. The stock has 5 warning signs investors should review.

WuXi Biologics (Cayman)'s quarterly finished goods declined from Dec. 2024 (MXN46 Mil) to Jun. 2025 (MXN39 Mil) and declined from Jun. 2025 (MXN39 Mil) to Dec. 2025 (MXN38 Mil).

WuXi Biologics (Cayman)'s annual finished goods increased from Dec. 2023 (MXN40 Mil) to Dec. 2024 (MXN46 Mil) but then declined from Dec. 2024 (MXN46 Mil) to Dec. 2025 (MXN38 Mil).

WuXi Biologics (Cayman) Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Inventories, Finished Goods Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.24 55.98 40.31 45.62 38.22

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.31 23.20 45.62 38.70 38.22
MEX:2269N
97GF Score
WuXi Biologics (Cayman) Inc MEX:2269N
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN38 Mil mean?
WuXi Biologics (Cayman) (MEX:2269N) has a Inventories, Finished Goods of MXN38 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Inventories, Finished Goods too high?
WuXi Biologics (Cayman)'s current Inventories, Finished Goods is MXN38 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Inventories, Finished Goods compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Inventories, Finished Goods of MXN38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Inventories, Finished Goods is MXN38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Inventories, Finished Goods of MXN38 Mil. The stock's GF Value™ is MXN54.50, compared to a current price of MXN62.53 — trading 14.7% above its estimated fair value. The current Inventories, Finished Goods is MXN38 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Inventories, Finished Goods is MXN38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued. The current stock price of MXN62.53 is trading 14.7% above its estimated GF Value™ of MXN54.50.

Key valuation signals for MEX:2269N:

  • Inventories, Finished Goods: MXN38 Mil
  • GF Value™: MXN54.50 vs. price of MXN62.53 (14.7% above fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for MEX:2269N

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.53
Price
MXN54.50
GF Value